AKTS three-lens brief
Evidence-based stock research on AKTS. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved -2.35% yesterday. · 50-day MA below 200-day MA (death-cross regime); price below both.
- Moved -2.35% yesterday.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 12.1pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $35.88 — 111% above current (8 analysts).
AKTS closed at $17.04 (-2.35%) as of 2026-11-12. Market cap: $947.76M. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $35.88 — 111% above current (8 analysts).. Concerns: moved -2.35% yesterday.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $3.23M, net income -$18.32M. Watching for: 2026-11-12 earnings release (today).
Why three lenses on AKTS, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AKTS across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/AKTS" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AKTS brief"></iframe>